Replies to post #138609 on Biotech Values

[DewDiligence]

The timing of this order seems non-coincidental insofar as the Gleevec patent case is currently being reviewed by India’s Supreme Court.

[apljack]

India Orders Bayer to License a Patented Drug

Natco’s drug will be for use only in India, the decision said.

Yeah, you can count on THAT happening!

aj

[DewDiligence]

Bayer appeals India’s compulsory license of Nexavar:

http://online.wsj.com/article/SB10001424052702304749904577385552118365454.html

…India's patent authority had in March forced Bayer to grant a compulsory license to Hyderabad, south India-based Natco Pharma Ltd. to sell a cheaper copy of Nexavar to ensure patients have access to the potentially life-saving medicine.

The patent authority, in its decision, noted that Bayer's patented drug sells for 284,428 rupees, or $5,319, for a monthly supply. Natco Pharma, the generics competitor that brought the case to the patent authority, sought to sell a month's supply of the generic version of Nexavar, sorafenib tosylate, at 8,800 rupees, or $164…

…To further complicate efforts by big Western pharmaceutical companies seeking to develop their businesses in India, Cipla Ltd.—one of India's largest generic drug manufacturer—has said it's cutting prices on its cancer medicines by up to 75%.

[DewDiligence]

Natco launches compulsory-licensed version of Nexavar in India:

http://www.thehindubusinessline.com/companies/article3613741.ece

Natco has priced the drug at Rs 8,880 ($159) for a pack of 120 tablets (a month’s course) against Rs 2.8 lakh ($5,000) for Bayer's drug.